Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company's Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Costa Panagos as CEO and a member of the Company's Board of Directors, effective immediately.

Syneos Health Appoints Costa Panagos as Chief Executive Officer

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ®  Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®, previously known as ZENEO® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, has engaged Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject's ZEPIZURE® innovative rescue therapy for epileptic seizures in the U.S. Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®. Syneos Health brings a strong U.S. presence and significant expertise in commercializing new therapies for Crossject.

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

AUSTIN, Texas--(BUSINESS WIRE)-- #clinicalresearch--Elligo Health Research® today announced it is expanding its Study Marketplace platform with Syneos Health.

Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health

Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers

Syneos Health Closes Transaction with Private Investment Firms

Civitas Resources

Hayward Holdings

NEW YORK , Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE: CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE: HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29.

Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

NEW YORK , Sept. 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Syneos Health, Inc..

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Syneos Health, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 25, 2023 - (NASDAQ: SYNH)

LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ: SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 25, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 17, 2022, Syneos disclosed that its rei.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (SYNH)

RADNOR, Pa. , Sept. 22, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Syneos Health, Inc. ("Syneos") (NASDAQ: SYNH).

Attention SYNH Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Syneos Health, Inc. (SYNH) and Encourages Investors to Contact the Firm

BENSALEM, Pa. , Sept. 21, 2023 /PRNewswire/ -- Law Offices of Howard G.

SYNH Investors Have Opportunity to Lead Syneos Health, Inc. Securities Fraud Lawsuit

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syneos Health, Inc. ("Syneos" or the "Company") (NASDAQ: SYNH).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syneos Health, Inc. - SYNH

LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Syneos Health, Inc. ("Syneos" or the "Company") (NASDAQ: SYNH) of a class action securities lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Syneos Health, Inc.(SYNH) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September 9, 2020 and November 3, 2022, both dates inclusive (the "Class Period"), of the important September 25, 2023 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - SYNH

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Attention Syneos Health, Inc. ("Syneos") (NASDAQ: SYNH) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between September 9, 2020 and November 3, 2022.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Syneos Investors of a Lead Plaintiff Deadline of September 25, 2023

LOS ANGELES, CA / ACCESSWIRE / September 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ: SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $500,000 to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)---- $SYNH #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Syneos Health, Inc. (“Syneos”) (NASDAQ: SYNH). The action charges Syneos with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Syneos's materially misleading statements and omissions to the pub.

Final Deadline Approaching for Syneos Health, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Syneos Health, Inc. (SYNH) Investors of September 25, 2023 Lead Plaintiff Deadline

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle's suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research.

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity

LOS ANGELES, CA / ACCESSWIRE / September 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , Sept. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September 9, 2020 and November 3, 2022, both dates inclusive (the "Class Period"), of the important September 25, 2023 lead plaintiff deadline.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SYNH

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Syneos Health, Inc. (NASDAQ:SYNH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/syneos-lawsuit-submission-form?prid=47666&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Syneos Health, Inc. (SYNH) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

RADNOR, Pa. , Sept. 10, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Syneos Health, Inc. ("Syneos") (NASDAQ: SYNH).

Syneos Health, Inc. (SYNH) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds SYNH Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Health (the “Acquisition”) by the Issuer and certain of its affiliated entities (such affiliates, together with the Issuer, the “Purchasing Entities”) and related refinancings. The Purchasing Entities were newly-formed entities established by a consortium of private investment funds led by Elliott Investment Management L.P. and its affiliates, Patient Square Capital, LP and its affiliates and Veritas Capital Fund Management, L.L.C. and its affiliates. If the sale of the Notes is not completed concurrently with the closing of the Acquisition, then the proceeds from the sale of the Notes will be placed into escrow until the closing of the Acquisition.

News for Syneos Health Stock (SYNH)